Background: Comprehensive and accurate assessment of symptoms experienced by patients undergoing lung radiotherapy (RT) is challenging. This study aims to evaluate the feasibility and utility of collecting acute toxicity information by using a patient-reported instrument, the Thoracic Symptom Self-Assessment Tool (TSSAT).
Methods: The TSSAT is based on the CTCAE v3.0(Common Toxicity Criteria of Adverse Events). All patients undergoing lung RT at our center from May 2008 to April 2009 were asked to complete the TSSAT on day 1 and weekly during RT. TSSAT scores were compared with clinician reporting of the same symptoms. Descriptive statistics and weighted kappa values were calculated to measure the agreement between patient- and clinician-reported acute toxicity.
Results: Of 300 consecutive patients approached, 49% (148/300) completed the TSSAT at least once. Patient participation and compliance were associated with treatment intent; radical (87%) vs. palliative (25%); P = <.0001. The average data completion rate by patients was 72%, and the average toxicity documentation rate by clinicians was 67%. Agreement between patients and clinicians was fair to moderate for most symptoms; the majority (>79%) of the differences were within one grade. Patients reported greater severity than clinicians for subjective symptoms. Clinicians graded greater severity than patients for the more observable symptoms.
Conclusions: The TSSAT has been shown to be feasible and accepted by patients receiving radical dose RT. Patient-reported assessments may improve acute symptom management in the future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cllc.2012.06.003 | DOI Listing |
Pract Radiat Oncol
January 2025
Department of Radiation Oncology, Allegheny Health Network, Pittsburgh, PA. Electronic address:
Purpose/objective: Partial breast irradiation (PBI) delivered with intensity modulated radiation therapy (IMRT) over five fractions every other day (QOD) represents an attractive, convenient method of delivering adjuvant radiation therapy for well selected patients without compromising oncologic or toxicity outcomes. Condensing this regimen to a week of treatment through consecutive daily delivery may further increase patient convenience, though comparison of toxicities between daily and QOD regimens are limited.
Materials/methods: We retrospectively reviewed 507 patients from an institutional registry undergoing PBI for DCIS or early-stage breast cancer (T1-2N0/x) from 2015 to 2022.
J Hazard Mater
January 2025
College of Environment and Resources, College of Carbon Neutral, Zhejiang A & F University, Hangzhou 311300, China.
p-Phenylenediamines (PPDs) are widely used as antioxidants in numerous rubber products to prevent or delay oxidation and corrosion. However, their derived quinones (PPD-Qs), generated through reactions with ozone, are ubiquitous in the environment and raise significant health and toxicity concerns. This review summarizes the current state of knowledge on environmental distribution and fate, human exposure, and biological toxicity of PPDs and PPD-Qs, and makes recommendations for future research directions.
View Article and Find Full Text PDFClin Toxicol (Phila)
January 2025
Pediatric Intensive Care Unit, Emergency Department, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Introduction: Veno-arterial extracorporeal membrane oxygenation is frequently considered and implemented to help manage patients with cardiogenic shock from acute poisoning. However, utilization of veno-venous extracorporeal membrane oxygenation in acutely poisoned patients is largely unknown.
Method: We conducted a retrospective study analyzing the epidemiologic, clinical characteristics and survival of acutely poisoned patients placed on veno-venous extracorporeal membrane oxygenation using the Extracorporeal Life Support Organization registry.
Front Nutr
January 2025
Aging and Metabolism Research Program, Oklahoma City, OK, United States.
Sulforaphane (SFN) is an isothiocyanate derived from cruciferous vegetables that has demonstrated anti-cancer, anti-microbial and anti-oxidant properties. SFN ameliorates various disease models in rodents (e.g.
View Article and Find Full Text PDFCureus
December 2024
Diabetes and Endocrinology, Prabhath Diabetes Care Centre, Udupi, IND.
This meta-analysis investigates the potential of allopurinol to prevent contrast-induced nephropathy (CIN), a common and serious complication of percutaneous coronary intervention (PCI). CIN is particularly prevalent among high-risk populations, including patients with chronic kidney disease (CKD) or acute coronary syndrome (ACS), where the administration of contrast agents can exacerbate renal injury. Allopurinol, a xanthine oxidase inhibitor, is known for its dual action in reducing oxidative stress and uric acid production, positioning it as a promising therapeutic candidate to mitigate CIN.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!